摘要：An Expert Panel convened by the National Lipid Association was charged with updating the recommendations on the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody therapy that were provided by the 2015 National Lipid Association Recommendations for the Patient-Centered Management of Dyslipidemia: Part 2. Recent studies have demonstrated the efficacy of these agents in reducing low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and have confirmed their excellent safety profile. A cardiovascular outcomes study has shown that these agents reduce incident atherosclerotic cardiovascular disease (ASCVD) events in patents with stable ASCVD and concomitant risk factors. The current update provides the Expert Panel's evidence-based recommendations on the clinical utility of PCSK9 inhibitors in patients with stable ASCVD, progressive ASCVD, LDL-C ≥ 190 mg/dL (including polygenic hypercholesterolemia, heterozygous familial hypercholesterolemia and the homozygous familial hypercholesterolemia phenotype) and very-high-risk patients with statin intolerance.
作者：Carl E,Orringer [1] ; Terry A,Jacobson [2] ; Joseph J,Saseen [3] ; Alan S,Brown [4] ; Antonio M,Gotto [5] ; Joyce L,Ross [6] ; James A,Underberg [7]
作者单位：Cardiovascular Division, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: carl.orringer@gmail.com. [1] Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA. [2] University of Colorado Anschutz Medical Campus, Aurora, CO, USA. [3] Division of Cardiology, Advocate Lutheran General Hospital, Park Ridge, IL, USA. [4] Cardiac Disease Prevention, Weill Cornell Medical College, New York, NY, USA. [5] University of Pennsylvania Health System, Philadelphia, PA, USA. [6] NYU School of Medicine & NYU Center for Prevention of Cardiovascular Disease, New York, NY, USA. [7]
期刊：《Journal of clinical lipidology》 880-890页
